Clinical trial
A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome
NCT00330564 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 31, 2006
- Completion date
- May 31, 2011
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hemangioblastoma, renal cell carcinoma, von hippel-lindau syndrome